A Changing Landscape for Biopharma

The biopharma R&D landscape is rapidly expanding, and new sources of innovation are offering patients hope with each new breakthroughs. Novel platforms such as cell and gene therapies and mRNA are complementing traditional platforms such as mAbs as biomanufacturers explore different solutions to developing new treatments. Also, the breadth of therapeutic areas impacted by innovation has expanded to include Alzheimer’s Disease, Parkinson’s, Infant Spinal Muscular Atrophy and others.

However, with all of this promise also brings new challenges for biomanufacturers from the discovery phase in the lab to specific scale-up and productions challenges through to commercialization. The COVID-19 crisis demonstrated the groundbreaking pace at which the biopharma industry has been able to innovate and in developing the mRNA vaccines, the industry proved the value of this new platform. It has also demonstrated the criticality of collaboration within the biopharma ecosystem, and the necessity for a strong relationship between suppliers and manufacturers as end-to-end support is key to success now and in the future.

This keynote presentation was given during BPI Europe, Vienna, May 17-19, 2022.

Presented by:

		Dr. Ger Brophy, Executive Vice President, Biopharma Production Dr. Ger Brophy is Executive Vice President, Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing Avantor’s Biopharma Production offering to support current and future customer needs. Prior to joining Avantor, Dr. Brophy held a variety of research and development, strategy, advanced systems, and business development positions with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics and Amersham for nearly 30 years. Dr. Brophy earned a Bachelor of Science in biotechnology, as well as a doctorate in molecular biology from Dublin City University in Ireland.